Asahi Kasei

ZOLL Selected to Exhibit TherOx SSO2 Therapy at Vizient Innovative Technology Exchange

Retrieved on: 
Monday, October 3, 2022
Cardiology, Data Management, Technology, Manufacturing, Other Health, Health, General Health, Other Technology, Medical Devices, Other Manufacturing, Hardware, Ventilation, Hospital, Asahi Kasei, Heart, Zenith Contract Services, Sleep apnea, Technology, Mohawk Innovative Technology, Exchange, FDA, Massachusetts Innovation & Technology Exchange, Death, LAD, EMS, Safety, Vizient, Inc., Heart failure, Diagnosis, Muscle tissue, Data management, CPR, Pharmaceutical industry, Medical device, STEMI

ZOLL, an Asahi Kasei company, has been selected to exhibit SuperSaturated Oxygen (SSO2) Therapy, which delivers high levels of dissolved oxygen directly to the heart following severe heart attack, at the Vizient Innovative Technology Exchange.

Key Points: 
  • ZOLL, an Asahi Kasei company, has been selected to exhibit SuperSaturated Oxygen (SSO2) Therapy, which delivers high levels of dissolved oxygen directly to the heart following severe heart attack, at the Vizient Innovative Technology Exchange.
  • Vizient, Inc , the nations largest member-driven health care performance improvement company, will hold the Exchange on October 17 in Dallas.
  • The Exchange is an exciting part of the Vizient Innovative Technology Program, which results in Innovative Technology contract awards for the qualified products.
  • The annual Innovative Technology Exchange is part of Vizients Innovative Technology Program that includes product review of supplier-submitted technologies by member-led councils and task forces.

Lyfebulb and Veloxis Pharmaceuticals Announce Finalists for 2022 Innovation Challenge in Organ Transplantation

Retrieved on: 
Monday, September 19, 2022
Dialysis, Organ transplantation, Twitter, MD, Justice, Conditional sentence, Creativity, LinkedIn, Population, Life, LAUNCH (Innovation Challenge), Patient, CEO, Digital Impact Awards Africa, Chicago Innovation Awards, Instagram, Solution, Doctor of Philosophy, Ammonia, Asahi Kasei, Diversity, Health care, Innovation, Transplant, Pharmaceutical industry, Facebook, CARY, Veloxis Pharmaceuticals, Equity

NEW YORK and CARY, N.C., Sept. 19, 2022 /PRNewswire/ --Lyfebulb, a patient-empowerment platform that connects patients with industry experts to support user-driven innovation, and Veloxis Pharmaceuticals, a fully integrated specialty pharmaceutical company, are pleased to announce 10 finalists for the 2022 "Transforming Organ Transplantation Through Innovation" Challenge.

Key Points: 
  • NEW YORK and CARY, N.C., Sept. 19, 2022 /PRNewswire/ --Lyfebulb, a patient-empowerment platform that connects patients with industry experts to support user-driven innovation, and Veloxis Pharmaceuticals, a fully integrated specialty pharmaceutical company, are pleased to announce 10 finalists for the 2022 "Transforming Organ Transplantation Through Innovation" Challenge.
  • "We are grateful for the opportunity to partner with Lyfebulb and are encouraged by the tremendous response to the Innovation Challenge, and the solutions our finalists have developed for this unique patient population," saysMark Hensley, CEO of Veloxis, an Asahi Kasei company.
  • "Veloxis shares their collective energy and dedication to the transplant community, as we continue to invest in solving the many unmet needs that remain in transplantation."
  • Veloxis Pharmaceuticals, Inc, an Asahi Kasei company, is a fully integrated specialty pharmaceutical company committed to improving the lives of transplant patients.

First Patient Enrolled in AMIHOT III Trial Investigating ZOLL’s Supersaturated Oxygen Therapy in Heart Attack Patients

Retrieved on: 
Wednesday, September 7, 2022
Cardiology, Software, Health, FDA, Medical Devices, Hospitals, Technology, Clinical Trials, Mortality, Triangle, Patient, University, Asahi Kasei, Safety, Muscle tissue, Hospital, STEMI, PCI, Carbon, Ventilation, Solution, Infarction, Ammonia, Incidence, Heart failure, Volunteering, Physician, Diagnosis, Data management, Dialysis, EMS, Health care, Principal, MVO, Multimedia, LAD, Rehabilitation hospital, MD, WakeMed, Instagram, FDA, Percutaneous coronary intervention, Twitter, Hamad Medical Corporation, Sleep apnea, Reflow soldering, Health, Life, CPR, University of New Mexico, Pharmaceutical industry, Medical device, Facebook

The patient, treated at WakeMed Health & Hospitals in North Carolina, received SSO2 Therapy, the first FDA-approved therapy shown to significantly reduce the size of damaged tissue (infarct) following percutaneous coronary intervention (PCI).

Key Points: 
  • The patient, treated at WakeMed Health & Hospitals in North Carolina, received SSO2 Therapy, the first FDA-approved therapy shown to significantly reduce the size of damaged tissue (infarct) following percutaneous coronary intervention (PCI).
  • TherOx SSO2 Therapy is currently indicated for patients who suffer LAD STEMI heart attacks with a high mortality rate treated within six hours of symptom onset.
  • SSO2 Therapy has been shown to reduce relative infarct size damage to the heart muscle by 26% over standard of care.
  • Besides demonstrating the safety and effectiveness of SSO2 Therapy, additional endpoints include incidence of microvascular obstruction (MVO), and outcomes measures such as heart failure readmissions and quality-of-life measures.

AMERICAN BATTERY FACTORY AND CELGARD ENTER STRATEGIC ALLIANCE AGREEMENT

Retrieved on: 
Tuesday, August 23, 2022
Lithium, Partnership, Asahi Kasei, LP, Solution, ABF, Lithium iron phosphate, Cell, LLC, Ion, LFP, Industry, Electric battery, Mobile phone, Renewable energy, Polypore

AMERICAN FORK, Utah, Aug. 23, 2022 /PRNewswire/ -- American Battery Factory Inc. (ABF) today announced it has signed a strategic alliance agreement with Celgard, LLC, subsidiary of Polypore International, LP, to provide Celgard® battery separators that will be integrated into its U.S.-manufactured Lithium Iron Phosphate (LFP) battery cells. As domestic production and demand for LFP batteries continues to increase, ABF is pleased to partner with Celgard to help to ensure supply security of a critical cell component.

Key Points: 
  • Celgard, leading dry-process battery separator manufacturer, and ABF will jointly develop new battery cell design and manufacturing processes, solutions and technologies.
  • AMERICAN FORK, Utah, Aug. 23, 2022 /PRNewswire/ -- American Battery Factory Inc. (ABF) today announced it has signed a strategic alliance agreement with Celgard, LLC, subsidiary of Polypore International, LP, to provide Celgard battery separators that will be integrated into its U.S.-manufactured Lithium Iron Phosphate (LFP) battery cells.
  • "Our partnership with Celgard is another pivotal milestone for American Battery Factory as we establish a domestic LFP battery cell supply chain," said Paul Charles, President and Chief Executive Officer of American Battery Factory.
  • American Battery Factory Inc., a Lithium Iron Phosphate (LFP) battery cell manufacturer, is developing the first-ever network of safe LFP cell giga-factories in the United States.

Celgard Enters into Strategic Alliance Agreement for High-Performance Lithium Iron Phosphate (LFP) Battery Separator Technology with American Battery Factory

Retrieved on: 
Monday, August 22, 2022
Technology, Research, LP, View, ABF, Cell, Multimedia, LLC, LFP, Ecosystem, Industry, Asahi Kasei, Electric battery, Renewable energy, Lithium, Polypore

CHARLOTTE, N.C., Aug. 22, 2022 /PRNewswire/ -- Celgard, LLC (Celgard), a subsidiary of Polypore International, LP, (Polypore) is pleased to announce it has entered into a strategic alliance agreement with American Battery Factory (ABF).

Key Points: 
  • CHARLOTTE, N.C., Aug. 22, 2022 /PRNewswire/ -- Celgard, LLC (Celgard), a subsidiary of Polypore International, LP, (Polypore) is pleased to announce it has entered into a strategic alliance agreement with American Battery Factory (ABF).
  • Under the terms of the agreement, Celgard will supply 100% of ABF's separator needs for LFP battery cells in the U.S.
  • Furthermore, Celgard and ABF will share resources to develop advanced technologies and next generation cells for LFP batteries.
  • American Battery Factory Inc., a lithium iron phosphate (LFP) battery cell manufacturer, is developing the first-ever network of safe LFP cell giga-factories in the United States.

Celgard Enters into Strategic Alliance Agreement for High-Performance Lithium Iron Phosphate (LFP) Battery Separator Technology with American Battery Factory

Retrieved on: 
Monday, August 22, 2022
LLC, Cell, Technology, LFP, Ecosystem, ABF, Research, Industry, LP, Asahi Kasei, Renewable energy, Electric battery, Polypore

CHARLOTTE, N.C., Aug. 22, 2022 /PRNewswire/ -- Celgard, LLC (Celgard), a subsidiary of Polypore International, LP, (Polypore) is pleased to announce it has entered into a strategic alliance agreement with American Battery Factory (ABF).

Key Points: 
  • CHARLOTTE, N.C., Aug. 22, 2022 /PRNewswire/ -- Celgard, LLC (Celgard), a subsidiary of Polypore International, LP, (Polypore) is pleased to announce it has entered into a strategic alliance agreement with American Battery Factory (ABF).
  • Celgard and ABF will undertake joint research projects to commercialize state-of-the-art next generation products for reliable high-technology prismatic lithium iron phosphate (LFP) batteries in the U.S.
  • Under the terms of the agreement, Celgard will supply 100% of ABF's separator needs for LFP battery cells in the U.S.
  • American Battery Factory Inc., a lithium iron phosphate (LFP) battery cell manufacturer, is developing the first-ever network of safe LFP cell giga-factories in the United States.

North America Battery Material Market 2022-2028 - Rising Focus of Manufactures Towards New Product Development Presents Opportunities - ResearchAndMarkets.com

Retrieved on: 
Friday, August 5, 2022
Technology, Batteries, Other Manufacturing, Manufacturing, Albemarle Corporation, Electronics, Computer, Center for Urban and Regional Analysis, Industry, LCO, Asahi Kasei, Television, Investment, NCA, NMC, Solvay S.A., Research, BASF, Recycling, COVID-19, Battery, Cathode, Safety, Hyco International Inc, SE, BASF SE, Mitsubishi Chemical Corporation, DOE, NCM, Electron, Lithium, Electric battery, Application, Arkema, American Elements

North America battery material market is expected to grow from US$ 5,620.44 million in 2021 to US$ 9,366.00 million by 2028.

Key Points: 
  • North America battery material market is expected to grow from US$ 5,620.44 million in 2021 to US$ 9,366.00 million by 2028.
  • Increasing demand for electric vehicles and growing demand from the electronic industry are among the major factors driving the battery material market growth in North America.
  • Based on material, the North America battery material market is segmented into anode, cathode, electrolyte, binders, coatings, and others.
  • Players operating in North America battery material market are highly focused on the development of high quality and innovative product offerings to fulfil the customer's requirements.

Asahi Kasei Bioprocess to Showcase Award-winning MOTIV™ Buffer Management Technology for Pharmaceutical Manufacturing at ACHEMA 2022

Retrieved on: 
Wednesday, July 27, 2022
Biotechnology, General Health, Medical Devices, Health, Pharmaceutical, Asahi Kasei, R, Data collection, Bioprocess, Solution, Family, Multimedia, Marketing, IBF, Technology, Patient, Farm, Operation Warp Speed, Buffer, Medicine, Mobile phone, RELX

Asahi Kasei Bioprocess America, subsidiary of diversified Japanese multinational company Asahi Kasei, will be featuring their MOTIV Buffer Management Technology at ACHEMA 2022 in Frankfurt this August.

Key Points: 
  • Asahi Kasei Bioprocess America, subsidiary of diversified Japanese multinational company Asahi Kasei, will be featuring their MOTIV Buffer Management Technology at ACHEMA 2022 in Frankfurt this August.
  • MOTIV can blend buffers from concentrates in small, single-use bags and is controlled with sensors to maintain and assure precision.
  • One of our strengths is not only having an innovative product, but also an extensive family of MOTIV systems to choose from.
  • 1 The OCELOT System Control is an Asahi Kasei Bioprocess proprietary technology that integrates and/or interfaces with plant-wide control systems in a universally compatible format, allowing for far-reaching data collection and analysis.

Lyfebulb and Veloxis Pharmaceuticals Seek Applicants for the Global 2022 Innovation Challenge in Organ Transplantation

Retrieved on: 
Tuesday, July 26, 2022
Asahi Kasei, Conditional sentence, LAUNCH (Innovation Challenge), Health care, Diagnosis, Industry, Twitter, Instagram, CEO, Dialysis, Digital Impact Awards Africa, Solution, The Ultimate Live Experience, Chicago Innovation Awards, Patient, LinkedIn, Life, Innovation, Ammonia, Transplant, Founder, Population, Pharmaceutical industry, Dentistry, Veloxis Pharmaceuticals, CARY, Facebook

NEW YORK and CARY, N.C., July 26, 2022 /PRNewswire/ -- Lyfebulb, a patient-empowerment platform that connects patients with industry experts to support user-driven innovation, and Veloxis Pharmaceuticals, an Asahi Kasei, fully integrated specialty pharmaceutical company, invite entrepreneurs to apply to their "Transforming Organ Transplantation Through Innovation" Challenge.

Key Points: 
  • NEW YORK and CARY, N.C., July 26, 2022 /PRNewswire/ -- Lyfebulb, a patient-empowerment platform that connects patients with industry experts to support user-driven innovation, and Veloxis Pharmaceuticals, an Asahi Kasei, fully integrated specialty pharmaceutical company, invite entrepreneurs to apply to their "Transforming Organ Transplantation Through Innovation" Challenge.
  • Additionally, Veloxis Pharmaceuticals may consider possible partnerships or investment opportunities with finalists beyond the challenge.
  • "At Veloxis, we are committed to improving the lives and outcomes of transplant patients across the globe," says Mark Hensley, CEO of Veloxis.
  • Veloxis Pharmaceuticals, Inc, an Asahi Kasei company, is a fully integrated specialty pharmaceutical company committed to improving the lives of transplant patients.

Geno and Aquafil begin pre-commercial production for plant-based nylon-6

Retrieved on: 
Wednesday, July 20, 2022
Asahi Kasei, Goal, Group, View, Cosmetics, Hypergymnasia, LULU, SAN, UL, Partnership, Multimedia, NASDAQ, Plastic, Palm oil, Life, ARCO, Genomatica, Biology, Engineering, ESG, HMD, Chemical, Unilever

SAN DIEGO and ARCO, Italy, July 20, 2022 /PRNewswire/ -- Sustainability leader Genomatica (Geno) alongside longtime collaborator Aquafil [ECNL:IM] successfully completed the first demonstration scale production runs for plant-based nylon-6. The material is intended to reshape the $22B nylon industry, enabling brands to meet demand from consumers for sustainable everyday materials from apparel to automotive parts to carpets. Geno and Aquafil have produced the first several tons of plant-based nylon-6 building block caprolactam, have converted it to nylon-6 polymer and are now in the process of transforming it for evaluation in nylon applications — such as yarns for textile and carpet and engineering plastics as part of pre-commercial quantities from demonstration production taking place in Europe.

Key Points: 
  • SAN DIEGO and ARCO, Italy, July 20, 2022 /PRNewswire/ -- Sustainability leader Genomatica ( Geno ) alongside longtime collaborator Aquafil [ECNL:IM] successfully completed the first demonstration scale production runs for plant-based nylon-6.
  • "Now, more than ever, global brands are taking action to incorporate sustainable materials into their products," said Christophe Schilling, Geno CEO.
  • Geno is harnessing biology to remake everyday products and materials built by and for the planet.
  • In response to the urgent climate crisis, Geno is developing and scaling sustainable materials derived from plant- or waste-based feedstocks instead of fossil fuels.